Review
Version 1
Preserved in Portico This version is not peer-reviewed
COVID-19: Rethinking the Lockdown Groupthink
Version 1
: Received: 14 October 2020 / Approved: 15 October 2020 / Online: 15 October 2020 (16:02:58 CEST)
Version 2 : Received: 3 November 2020 / Approved: 4 November 2020 / Online: 4 November 2020 (10:14:33 CET)
Version 2 : Received: 3 November 2020 / Approved: 4 November 2020 / Online: 4 November 2020 (10:14:33 CET)
A peer-reviewed article of this Preprint also exists.
Joffe AR. COVID-19: Rethinking the lockdown groupthink. Frontiers in Public Health 2021;9:625778 Joffe AR. COVID-19: Rethinking the lockdown groupthink. Frontiers in Public Health 2021;9:625778
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused the Coronavirus Disease 2019 (COVID-19) worldwide pandemic in 2020. In response, most countries in the world implemented lockdowns, restricting their population’s movements, work, education, gatherings, and general activities in attempt to ‘flatten the curve’ of COVID-19 cases. The public health goal of lockdowns was to save the population from COVID-19 cases and deaths, and to prevent overwhelming health care systems with COVID-19 patients. In this narrative review I explain why I changed my mind about supporting lockdowns. First, I explain how the initial modeling predictions induced fear and crowd-effects [i.e., groupthink]. Second, I summarize important information that has emerged relevant to the modeling, including about infection fatality rate, high-risk groups, herd immunity thresholds, and exit strategies. Third, I describe how reality started sinking in, with information on significant collateral damage due to the response to the pandemic, and information placing the number of deaths in context and perspective. Fourth, I present a cost-benefit analysis of the response to COVID-19 that finds lockdowns are far more harmful to public health than COVID-19 can be. I close with some suggestions for moving forward.
Keywords
COVID-19; Public Health; Lockdowns; Cost-benefit analysis
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment